New research suggests a protein primarily associated with Parkinson’s disease may explain why women are disproportionately affected by Alzheimer’s. A study by the Mayo Clinic, involving 415 participants, found that abnormal levels of the protein alpha-synuclein accelerate the buildup of tau—a hallmark of Alzheimer’s—up to 20 times faster in women compared to men. This disparity in disease progression highlights a crucial biological difference that has long been overlooked in Alzheimer’s research.
The Role of Alpha-Synuclein
Alpha-synuclein, when misfolded, appears to act as an accelerant in the development of Alzheimer’s pathology. While both men and women produce this protein naturally, its malfunction seems to trigger a more rapid accumulation of tau in female brains. This suggests that the presence of abnormal alpha-synuclein doesn’t simply indicate disease presence; it influences how fast the disease unfolds, particularly in women.
Why this matters: Alzheimer’s has historically been treated as a uniform disease, but this study underscores the need for sex-specific research. Ignoring these biological differences hinders the development of effective treatments and diagnostic tools.
Biological Factors at Play
Researchers hypothesize that hormonal shifts, specifically a sharp decline in estrogen levels during menopause, may play a role. Estrogen is known to offer some protection against toxic protein buildup in the brain, and its absence could leave women more vulnerable. Another possibility is that misfolded alpha-synuclein exacerbates inflammation, worsening tau clumping—a process that may be amplified in female brains for yet unknown reasons.
Implications for Diagnosis and Treatment
The findings have practical implications for both diagnosis and treatment strategies. Currently, Alzheimer’s, Parkinson’s, and related dementias can overlap in symptoms, making accurate differentiation difficult. Identifying these protein-level differences could lead to more precise diagnostic tests and tailored clinical trials.
“Recognizing these sex-specific differences could help us design more targeted clinical trials and ultimately more personalized treatment strategies,” explains neuroradiologist Kejal Kantarci.
The study’s relatively short follow-up period (just over a year) warrants further investigation. However, the data already points toward a clear need to reassess how Alzheimer’s is understood and treated, especially in light of the gender imbalance in prevalence.
Ultimately, this research opens a new avenue for understanding why women are at greater risk of dementia and reinforces the importance of biological factors in disease progression.
